Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study

OBJECTIVE: We evaluated the effects of ursodeoxycholic acid (UDCA) on glucagon-like peptide-1 (GLP-1) secretion and glucose tolerance in patients with type 2 diabetes with chronic liver disease. RESEARCH DESIGN AND METHODS: Japanese patients with type 2 diabetes (glycated hemoglobin (HbA1c) levels ≥...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMJ Open Diabetes Res Care
Egile Nagusiak: Shima, Kosuke Robert, Ota, Tsuguhito, Kato, Ken-ichiro, Takeshita, Yumie, Misu, Hirofumi, Kaneko, Shuichi, Takamura, Toshinari
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2018
Gaiak:
Emerging Technologies, Pharmacology and Therapeutics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5873545/
https://ncbi.nlm.nih.gov/pubmed/29607050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjdrc-2017-000469
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak